ACRX... Zalviso Phase 3 trial started Sept. 2016...Results due mid 2017...FDA (07/31?) so watch...
https://finance.yahoo.com/news/acelrx-pharmaceuticals-zalviso-recognized-innovative-110000609.html "Since ZALVISO was approved by the EMA in 2015, the positive feedback that we and our licensee, Grunenthal, have received from patients and healthcare providers who have used ZALVISO is strong evidence that a well-designed medical product can have a meaningful impact on patient care. The Red Dot Award recognizes this fusion of design, function and patient benefit. To have ZALVISO selected from more than 5,500 entries from 54 countries is truly rewarding."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.